12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Evotec, J&J deal

Evotec granted Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary exclusive, worldwide rights to develop and commercialize Evotec's portfolio of oral small molecule NMDA receptor NR2B subtype antagonists for depressive disorders. Evotec will receive $2 million up...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >